Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (12)
- Advertising (9)
- Manufacturing (9)
- Scheduling (national classification system) (9)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Clinical trials (3)
- Legislation (3)
- Medicinal cannabis hub (3)
- Import and export (2)
- Breast implant hub (1)
- Committees and advisory bodies (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
185 result(s) found, displaying 76 to 100
-
-
Corporate reportsThese guidelines apply to company-sponsored post-marketing surveillance studies of drug safety and toxicity
-
Corporate reportsAdvancing Australia's health through international regulatory engagement
-
Corporate reportsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
Corporate reportsRead our clinician information sheet on opioid analgesic tapering.
-
-
Corporate reportsThe July-December 2020 Half Yearly Performance Statistics Report is now available
-
Corporate reportsThe Australian Government has accepted all 22 recommendations
-
Corporate reportsGuidance for procurement areas in hospitals, aged care residential facilities and other facilities.
-
-
-
Corporate reportsTargets have been met for the measures under the six KPIs
-
Corporate reportsProposal to prevent the uptake of nicotine containing e-cigarettes by ever users (adolescents and young adults), to support smoking cessation and to reduce nicotine poisonings of children
-
Corporate reportsInsights into therapeutic goods safety regulatory activity for our recalls program.
-
Corporate reportsInsights into manufacturing quality regulatory activity.
-
Corporate reportsThe TGA has published insights into recalls and GMP regulation for 2019-20.
-
Corporate reportsResults of communication developmental research undertaken to inform consumer and health professional communication activities for the opioid regulatory reforms.
-
Corporate reportsRead our clinician information sheet on opioid analgesic tapering: summary.
-
Corporate reportsThe TGA 2019-20 Annual Performance Statistics Report has now been published.
-
Corporate reportsThis Regulation Impact Statement (RIS) is intended to assist the Australian Government in reaching a decision to address the issues relating to the safe use of sports supplements in Australia.
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Corporate reportsFinal Report on the impact of advertising reforms from the Expert Panel Review of Medicines and Medical Devices Regulation, and other initiatives
-
Corporate reportsThe independent review is complete and the report now published.
-
Corporate reportsA rapid literature review of safety and performance issues
-
Corporate reportsGuidance for reducing assessment fees for ARTG application audits and TGA conformity assessments of medical devices (including IVDs).